Patrick Borgen, MD
2017 Giants of Cancer Care® Chair
Patrick Borgen, MD
Director, Brooklyn Breast Cancer Program
Maimonides Hospital
Brooklyn, NY
Dr. Patrick I. Borgen is Chairman of Surgery at Maimonides Medical Center in Brooklyn, New York. He also heads the Breast Center at the newly built Maimonides Cancer Center. Recruited from Memorial Sloan Kettering, Dr. Borgen was Chief, Breast Service; Head, Breast Cancer Research Laboratory; and Director, Breast Cancer Disease Management Team at Memorial. He holds a faculty position at Cornell University Medical College.

Dr. Borgen earned a BS Magna Cum Laude in Biomedical Engineering at Tulane and his MD at Louisiana State University. His postdoctoral work includes an internship and a residency at Ochsner Medical Institutions in New Orleans, Louisiana (where he was Chief Resident), and a clinical research fellowship at Memorial Sloan Kettering. In addition, he received management training in the Program for Chiefs of Clinical Services at the Harvard School of Public Health.

Dr. Borgen has received numerous research grants from the National Institutes of Health, the American Cancer Society, the Army, and the
National Cancer Institute. Widely published in peer-reviewed publications, Dr. Borgen is on the Editorial Board of Annals of Surgical Oncology and on the Peer Review Board of The Journal of the American Medical Association. He is Guest Editor for Surgery, Annals of Surgery, The Journal of the American College of Surgeons, Breast Diseases, Breast Diseases Quarterly, The Breast Journal, The Lancet, Archives of Surgery, and Journal of Clinical Oncology. He is Editor of 3 major textbooks on breast disease and has contributed chapters to 15 other texts. To date, he has published 200 articles in peer-reviewed journals, 141 abstracts, and 15 editorials.

Dr. Borgen has been Chairman of the American College of Surgeons Breast Cancer Trials Group and a member of the Executive Board of Directors of the American Society for the Study of Breast Disease. He is currently on the Executive Boards of the Breast Cancer Alliance, Inc., and of Tulane University, and is a member of the American Joint Committee on Cancer, Breast Task Force.
Maurie Markman, MD
Maurie Markman, MD
President, Medicine & Science
Cancer Treatment Centers of America
Philadelphia, PA
A nationally-renowned oncologist, Dr. Markman is President of Medicine and Science at Cancer Treatment Centers of America. Previously, he was Senior Vice President of Clinical Affairs and National Director of Medical Oncology. Dr. Markman has more than 20 years of experience in cancer treatment and gynecologic research at some of the country's most recognized facilities.

Most recently, Dr. Markman served as the Vice President for Clinical Research, Chairman of the Department of Gynecologic Medical Oncology at MD Anderson Cancer Center in Houston, Texas. Where he also served as a professor of medicine. He is a member of numerous professional organizations, including, but not limited to, the American College of Physicians, the American Society of Clinical Oncology, the American Association for Cancer Research, the American Medical Association, the American Society of Hematology, the American Society of Internal Medicine, the International Gynecologic Cancer Society, and the Society of Gynecologic Oncologists.
George D. Demetri, MD
George D. Demetri, MD
Dana-Farber Cancer Institute
Harvard Cancer Center
Boston, MA
Dr. Demetri is Director of the Center for Sarcoma and Bone Oncology at DFCI, Director of the Ludwig Center at Dana-Farber/Harvard Cancer Center, and Executive Director for Clinical and Translational Research at the Ludwig Institute for Cancer Research.

Dr. Demetri's research and clinical interests have focused on mechanism-based drug development for solid tumors, with a particular emphasis on molecularly-defined subsets of sarcomas such as gastrointestinal stromal tumors. Work from the multidisciplinary team at Dana-Farber/Harvard has contributed to the development of several new drugs for sarcomas and other malignancies, including imatinib (Gleevec), sunitinib (Sutent), dasatinib (Sprycel), trabectedin (Yondelis), and pazopanib (Votrient), as well as other new targeted therapies in development. In addition, as the medical oncologist on the Scientific Advisory Board of Plexxikon, he was instrumental in the discovery and development of vemurafenib (Zelboraf). Dr. Demetri serves as Co-chair of the Medical Advisory Board for the Sarcoma Foundation of America, as well as several scientific and editorial advisory boards. With an interest in internet-based medical and social network technologies, he is developing a novel Web-based rapid learning community for sarcomas within CancerCommons.org.
Hope S. Rugo, MD
Hope S. Rugo, MD
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Dr. Rugo is a medical oncologist and hematologist specializing in breast cancer research and treatment. A clinical professor of medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at UCSF in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer. She entered the field of breast cancer in order to incorporate novel therapies based on an understanding of the biology of cancer.

Dr. Rugo is the Director of the Breast Oncology Clinical Trials Program and is the principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early- and late-stage breast cancer. She is an active member of the national cooperative group, CALGB; a founding member of the Breast Cancer Research Consortium; and an investigator in the UCSF Breast SPORE (the Bay Area Specialized Program of Research Excellence in Breast Cancer).
Heather Wakelee, MD
Heather Wakelee, MD
Associate Professor of Medicine
Thoracic Oncology
Stanford, CA
Dr. Wakelee is a clinical investigator with a focus in lung cancer and other thoracic malignancies. Along with her other colleagues in thoracic medical oncology at Stanford, she is focused on clinical trials with agents that are specifically targeted to known mutations in lung cancer. These trials focus on EGFR-targeted agents and drugs that overcome resistance to traditional EGFR-targeted drugs. She is also focusing on Met-targeted drugs such as onartuzumab, tivantinib, and cabozantinib. Earlier work on anti-angiogenesis agents continues, as well.

Dr. Wakelee is an active member of the Eastern Cooperative Oncology Group and is the prinicipal investigator of a large adjuvant trial for patients with completely resected lung cancer who are randomized to chemotherapy or chemotherapy plus bevacizumab. Dr. Wakelee is also involved in several collaborative efforts with her colleagues in thoracic surgery and radiation oncology (a multidisciplinary trial for patients with stage III non-small cell lung cancer and cyberknife protocols for early stage patients not eligible for surgery), as well as in pulmonary medicine (analysis of blood samples for circulating lung tumor cells and other basic science projects).
Daniel George, MD
Daniel George, MD
Professor of Medicine
Professor in Surgery
Member of the Duke Cancer Institute
Dr Daniel George is Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology in the Duke University School of Medicine. He also has appointments in the Duke Clinical Research Institute and the Duke Cancer Institute where he is the Director of Genitourinary (GU) Oncology. He is an internationally recognized clinical researcher and thought leader in GU malignancies, with over 150 peer-reviewed publications. His areas of research include new drug development and biomarkers of GU cancers with an emphasis on signal transduction pathways and angiogenesis. Dr. George has led the Duke site for the Department of Defense (DOD) Prostate Cancer Clinical Trials Consortium since 2006, specializing in Phase I and II studies in prostate cancer. He is also the PI of the MaRCC registry in advanced renal cell carcinoma and Co-PI of IRONMAN, an international, multi-sponsor supported registry in advanced prostate cancer. Dr. George serves on the ASCO scientific committee for non-prostate cancer, the Alliance GU scientific committee, NCI GU Steering Committee and the NCI Renal Task Force. He also serves as a senior editor for Clinical Cancer Research and Clinical Advances in Hematology and Oncology.
Alessandra Ferrajoli, MD
Alessandra Ferrajoli, MD
Professor of Medicine
Department of Leukemia
The University of Texas M.D. Anderson Cancer Center
Houston, TX
Dr Alessandra Ferrajoli is an academic hematologist/oncologist practicing in the Leukemia Department at the University of Texas, MD Anderson since 1998. Her main area of interest includes the treatment and biology of chronic lymphocytic leukemia and its variants, and treatment of elderly patients with acute and chronic leukemia. In these fields she has authored and co-authored more than two hundred publications in peer-reviewed journals. She serves on numerous journal editorial boards and participates in grant proposal study sessions for several US and European Agencies. She is a member of several professional societies such as the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), International Society of Geriatric Oncology (SIOG), the European Society for Medical Oncology (ESMO), and the European Hematology Association (EHA).
Ghassan K. Abou-Alfa, MD
Matthew C. Abramowitz, MD
Kenneth C. Anderson, MD
Robert H. I. Andtbacka, MD, CM
Robert C. Bast, Jr., MD
Johanna Bendell, MD
Michael J. Birrer, MD, PhD
Kimberly Blackwell, MD
Clara D. Bloomfield, MD
  Patrick I. Borgen, MD
Julie Brahmer, MD
Adam Brufsky, MD, PhD
Paul A. Bunn, Jr., MD
Howard A. Burris III, MD
Harold J. Burstein, MD, PhD
John C. Byrd, MD
Philippa Cheetham, MD
Ezra Cohen, MD
Robert Coleman, MD
Raoul Concepcion, MD
E. David Crawford, MD
Massimo Cristofanilli, MD
Riccardo Dalla-Favera, MD
Adil Daud, MD
George D. Demetri, MD
Vincent T. DeVita, Jr., MD
Alessandra Ferrajoli, MD
Robert A. Figlin, MD
Steven E. Finkelstein, MD
Barbara Fowble, MD
Emil Freireich, MD, DSc (Hon.)
David Gandara, MD
  Daniel George, MD
Lori J. Goldstein, MD
Andre Goy, MD, MS
Axel Grothey, MD
Omid Hamid, MD
Daniel A. Hamstra, MD, PhD
Roy S. Herbst, MD, PhD
Gabriel N. Hortobagyi, MD
Maha H. Hussain, MB, ChB
Richard W. Joseph, MD
Hagop M. Kantarjian, MD
Philip W. Kantoff, MD
Beth Y. Karlan, MD
Howard Kaufman, MD
V. Suzanne Klimberg, MD
Robert A. Kyle, MD
Mario E. LaCouture, MD
Corey Langer, MD
Minetta C. Liu, MD
Sagar Lonial, MD
Charles L. Loprinzi, MD
Jason J. Luke, MD
Thomas J. Lynch, Jr., MD
Eleftherios P. Mamounas, MD, MPH
  Maurie Markman, MD
John L. Marshall, MD
Robert J. Mayer, MD
John Minna, MD
Monica Morrow, MD
Franco M. Muggia, MD
Susan O'Brien, MD
William K. Oh, MD
Joyce O'Shaughnessy, MD
Sumanta Kumar Pal, MD
Edith A. Perez, MD
Daniel P. Petrylak, MD
Ramesh K. Ramanathan, MD
  Hope S. Rugo, MD
A. Oliver Sartor, MD
Charles L. Sawyers, MD
Mark Socinski, MD
Debu Tripathy, MD
R. Michael Tuttle, MD
Jonathan D. Tward, MD, PhD
Alan P. Venook, MD
Nicholas J. Vogelzang, MD
Everett Vokes, MD
  Heather Wakelee, MD
Patrick C. Walsh, MD
Jeffrey S. Weber, MD, PhD
Howard L. West, MD
William K. Wierda, MD, PhD
Lori J. Wirth, MD
Jedd D. Wolchok, MD, PhD
William C. Wood
* Giants of Cancer Care® Inductees | Advisory Board
Program Information:
Nominate
Sponsor
News
Previous Inductees:
2013 | 2014
2015 | 2016
2017
Connect: